Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.asjsur.2024.08.092 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cyclophilin J inhibited oxidative stress and apoptosis in triple-negative breast cancer cell through activating the PI3K/Akt signaling pathway.
Toxicol Appl Pharmacol
September 2025
Department of Radiation Oncology, the Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China. Electronic address:
Triple-negative breast cancer (TNBC) was a highly aggressive and metastatic subtype of breast cancer characterized by a poor prognosis and limited treatment options. Clarifying the underlying molecular mechanisms was of significant clinical importance. In this study, we We plotted Kaplan-Meier survival curves based on data from the Human Cancer Database and found that elevated CYPJ expression increased patient mortality risk and decreased survival rates.
View Article and Find Full Text PDFTargeting the KRAS-p38-ATF4 axis enhances the therapeutic sensitivity of the peptide PDBAG1 in ovarian cancer via stress response modulation.
Eur J Pharmacol
September 2025
General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, PR China. Electronic address:
We previously screened a peptide PDBAG1 that remarkably inhibited triple-negative breast cancer, and found that its target was C1QBP. Recently, C1QBP has been reported as a potential tumor marker in ovarian cancer, which of the mortality rate ranks first among malignant tumors of the female reproductive tract. However, it is unclear whether and how PDBAG1 plays a regulatory role in ovarian cancer.
View Article and Find Full Text PDFChitosan/dialdehyde starch coating onto l-tyrosine and curcumin intercalated layered double hydroxide for improved the therapeutic effects of breast cancer.
Int J Biol Macromol
September 2025
Polymer Research Laboratory, Department of Organic and Biochemistry, Faculty of Chemistry, University of Tabriz, Tabriz, Iran; Research Center for Pharmaceutical Nanotechnology (RCPN), Biomedicine Institute, Tabriz University of Medical Science, Tabriz, Iran. Electronic address:
This study aimed to develop an innovative pH-sensitive bio-hydrogel containing curcumin (CUR) and l-tyrosine (Tyr) intercalated layered double hydroxide-modified chitosan (CS)/dialdehyde starch (DAS) (DAS-CS@Tyr-CUR@LDH) to facilitate the controlled release of Tyr and CUR, thereby enhancing their bioavailability and therapeutic effects. The entrapment efficiencies of Tyr and CUR were obtained at 79.31 ± 5.
View Article and Find Full Text PDFENPP1 inhibitor with ultralong drug-target residence time as an innate immune checkpoint blockade cancer therapy.
Cell Rep Med
August 2025
Department of Biochemistry, Stanford University, Stanford, CA 94305, USA; ChEM-H Institute, Stanford University, Stanford, CA 94305, USA; Arc Institute, Palo Alto, CA 94304, USA. Electronic address:
Only one in five patients respond to immune checkpoint inhibitors, which primarily target adaptive immunity. Ectonucleotide pyrophosphatase/phophodiesterase 1 (ENPP1), the dominant hydrolase of 2'3'-cyclic-GMP-AMP (cGAMP) that suppresses downstream stimulator of interferon genes (STING) signaling, has emerged as a promising innate immunotherapy target. However, existing ENPP1 inhibitors have been optimized for prolonged systemic residence time rather than effective target inhibition within tumors.
View Article and Find Full Text PDFPirin does not bind to p65 or regulate NFκB-dependent gene expression but does modulate cellular quercetin levels.
Mol Pharmacol
August 2025
Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan; "Nicholas V. Perricone, M.D.," Division of Dermatology, Department of Medicine, Michigan State University, East Lansing, Michigan. Electronic address:
Pirin is a nonheme iron-binding protein with a variety of proposed functions, including serving as a coactivator of p65 NFκB and quercetinase activity. We report here, failure to confirm pirin's primary proposed mechanism, binding of Fe(III)-pirin and p65. Analytical size exclusion chromatography and fluorescence polarization studies did not detect an interaction.
View Article and Find Full Text PDF